Diamyd Medical (DMYD-B.ST)

Executive Summary

Diamyd Medical is a Swedish clinical-stage biopharmaceutical company dedicated to developing precision immunotherapies for type 1 diabetes (T1D). Its lead candidate, Diamyd, is an antigen-specific immunotherapy designed to preserve endogenous insulin production by targeting the GAD65 autoantigen. The company is advancing a Phase 3 trial (DIAGNODE-3) evaluating intralymphatic administration of Diamyd in genetically defined patients with recent-onset T1D. This precision medicine approach aims to halt disease progression and reduce dependence on exogenous insulin. Diamyd Medical is publicly traded on Nasdaq Stockholm First North and has a market capitalization of approximately $172 million as of early 2026. Diamyd's strategy leverages genetic biomarkers to identify responders, potentially increasing the likelihood of regulatory success. The DIAGNODE-3 trial's primary endpoint is the change in stimulated C-peptide levels, a measure of beta-cell function, after 12 months. Positive results could support a registration application in Europe and the US. The company also explores combinations with other therapies and maintains a robust intellectual property portfolio. With a focused pipeline and a clear unmet medical need, Diamyd represents a high-risk, high-reward opportunity in the precision diabetes space.

Upcoming Catalysts (preview)

• Q4 2026Phase 3 DIAGNODE-3 Topline Data45% success
• H1 2027Regulatory Filing in Europe (EMA)50% success
• Q2 2027Potential Partnership or Licensing Deal30% success